Orchestra BioMed, Inc.

Health Sciences Acquisitions Corporation 2 (Nasdaq: HSAQ) was a healthcare-focused blank-check company that completed its initial public offering in 2020. The vehicle was structured to pursue targets within the biotech and pharmaceutical sector. In July 2022, HSAQ announced a definitive business combination agreement with Orchestra BioMed, Inc., a clinical-stage bioelectronic medicine company developing implantable device therapies for cardiovascular conditions including hypertension and heart failure. The transaction subsequently closed, marking Orchestra BioMed's transition into the public markets. HSAQ's status is now listed as closed following completion of the combination. For complete filing history, deal timelines, and SPAC analytics on HSAQ and thousands of other vehicles, sign up for full data access at SpacDesk.

SPAC Counterparty (1)